These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11390120)

  • 21. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women.
    de Vrijer B; Snijders MP; Troostwijk AL; Thé S; Iding RJ; Friese S; Smit DA; Schierbeek JM; Brandts H; van Kempen PJ; van Buuren I; Monza G
    Maturitas; 2000 Jan; 34(1):47-55. PubMed ID: 10687882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study.
    Nielsen TF; Ravn P; Bagger YZ; Warming L; Christiansen C
    Osteoporos Int; 2004 Feb; 15(2):168-74. PubMed ID: 14647880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial.
    Buster JE; Koltun WD; Pascual ML; Day WW; Peterson C
    Obstet Gynecol; 2008 Jun; 111(6):1343-51. PubMed ID: 18515518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.
    Endrikat J; Graeser T; Mellinger U; Ertan K; Holz C
    Maturitas; 2007 Oct; 58(2):201-7. PubMed ID: 17889463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
    Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
    Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women.
    Archer DF; Pickar JH; MacAllister DC; Warren MP
    Menopause; 2012 Jun; 19(6):622-9. PubMed ID: 22282101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms.
    Speroff L
    Obstet Gynecol; 2003 Oct; 102(4):823-34. PubMed ID: 14551014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
    Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
    Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of abrupt discontinuation versus gradual dose reduction of postmenopausal hormone therapy on hot flushes.
    Cunha EP; Azevedo LH; Pompei LM; Strufaldi R; Steiner ML; Ferreira JA; Peixoto S; Fernandes CE
    Climacteric; 2010 Aug; 13(4):362-7. PubMed ID: 20151792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study.
    De Aloysio D; Rovati LC; Giacovelli G; Setnikar I; Bottiglioni F
    Arzneimittelforschung; 2000 Mar; 50(3):293-300. PubMed ID: 10758784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study.
    Stevenson JC; Durand G; Kahler E; Pertyński T
    Maturitas; 2010 Nov; 67(3):227-32. PubMed ID: 20688442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes.
    Gerlinger C; Gude K; Schmelter T; Schaefers M; Endrikat J
    Climacteric; 2015; 18(4):512-7. PubMed ID: 26000627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
    Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
    Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulsed estrogen therapy improves postmenopausal quality of life: a 2-year placebo-controlled study.
    Nielsen TF; Ravn P; Pitkin J; Christiansen C
    Maturitas; 2006 Jan; 53(2):184-90. PubMed ID: 16368471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial.
    Engin-Ustün Y; Ustün Y; Meydanli MM; Kafkasli A
    Gynecol Endocrinol; 2006 Dec; 22(12):676-9. PubMed ID: 17162709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
    Hattersley G; Harris AG; Simon JA; Constantine GD
    Menopause; 2017 Jan; 24(1):92-99. PubMed ID: 27575546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
    Mizunuma H
    Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.